Financial Performance - In 2024, the company achieved operating revenue of 803.73 million yuan, a year-on-year increase of 5.75% [1] - The net profit attributable to shareholders was 106.43 million yuan, a decrease of 21.01% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 83.47 million yuan, down 26.88% year-on-year, primarily due to increased personnel costs [1] - In Q1 2025, the company reported operating revenue of 176.47 million yuan, a decline of 4.37% year-on-year [2] - The net profit attributable to shareholders in Q1 2025 was 7.43 million yuan, a significant drop of 67.32% year-on-year [2] - The net profit after deducting non-recurring gains and losses in Q1 2025 was 4.83 million yuan, down 75.34% year-on-year [2] Contractual and Operational Metrics - As of the end of 2024, the company had a total non-tax contract amount of 1.889 billion yuan, a year-on-year increase of 0.38% [2] - The company signed new contracts worth 1 billion yuan in 2024 [2] - By March 31, 2025, the company had undertaken over 3,800 clinical trial projects, serving 1,300 clients across more than 200 cities [2] Industry Trends and Developments - From 2015 to 2024, the number of innovative drugs approved for the first time in China increased from 3 to 39, a growth of 12 times, positioning China as the second globally [3] - The number of innovative drugs that initiated clinical trials in China rose from 124 in 2015 to 704 in 2024, making China the leader globally [4] - In 2024, Chinese pharmaceutical companies achieved a historic breakthrough in licensing out, with total transaction amounts reaching 51.9 billion USD, including upfront payments of 4.1 billion USD [4] - In Q1 2025, there were 33 licensing out transactions, a year-on-year increase of 32%, with total transaction amounts reaching 36.6 billion USD, an increase of over 250% [4] Clinical Trial Registration - In 2024, the total number of registered clinical trials in China reached 4,900, a year-on-year increase of 13.9% [5] - Among these, 2,539 new drug clinical trials were registered, reflecting a 9.3% increase year-on-year [5] - Class 1 drugs accounted for 68.3% of the new drug clinical trials, with anti-tumor drugs making up 39% of the total [5]

编号：2025-005 投资者关系 活动类别 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 券商策略会 □其他 参与单位 名称及人员 姓名 易方达基金 工银瑞信 中欧基金 兴证全球基金 兴银基金 华夏基金 安信基金 国投瑞银基金 鹏华基金 财通基金 中庚基金 北信瑞丰基金 太平基金 银河基金 富国基金 上银基金 长江养老 人保养老 凯石基金 建信养老金 中金资管 山证资管 浙商资管 百年保险资管 康曼德资本 红杉资本 川江投资 华能贵诚信托 中金证券 国海证券 民生证券 东北证券 国盛证券 信达证券 中泰证券 国泰海通证券 华西证券 鹤禧投资 拾贝投资 国泰君安资管 和谐汇一 中银证券资管 等 53 家机构 62 人 时间 2025 年 5 月 16 日、2025 年 5 月 19 日、2025 年 5 月 23 日、 2025 年 5 月 27 日—2025 年 5 月 28 日、2025 年 5 月 30 日、 2025 年 6 月 4 日、2025 年 6 月 10 日、2025 年 6 月 12 日 地点 上海、北京、宁波 上市公司接 待人员姓名 董事会秘 ...

Group 1: Company Overview and Financial Performance - Proris is a data-driven clinical research service provider focused on patient-centered approaches, enhancing the quality and efficiency of clinical trials in China [2] - In 2024, the company achieved operating revenue of CNY 803.73 million, a year-on-year increase of 5.75%, while net profit attributable to shareholders decreased by 21.01% to CNY 106.43 million [2] - For Q1 2025, operating revenue was CNY 176.47 million, a decline of 4.37%, with net profit dropping 67.32% to CNY 7.43 million [2] Group 2: Contract and Project Management - The company signed new contracts worth CNY 1 billion in 2024, with a total contract amount of CNY 1.889 billion by the end of the year, reflecting a 0.38% increase year-on-year [2] - As of March 31, 2025, Proris has undertaken over 3,800 SMO projects, with 2,250 currently in execution, and a total workforce of 4,277 employees [2] Group 3: Shareholder Value and Dividends - In 2024, the total cash dividend amounted to CNY 19.88 million, accounting for 18.68% of the annual net profit [3] - Cumulative cash dividends from 2022 to 2024 reached CNY 40.77 million [3] Group 4: Industry Trends and Challenges - The SMO industry is entering a new development phase, with increasing concentration among leading firms due to enhanced client resources and regulatory support [3] - In 2024, the number of drug clinical trials registered in China reached 4,861, a 15.60% increase from 4,205 in 2023, indicating a robust growth trend in biopharmaceutical R&D [3] Group 5: Cost Management and Operational Efficiency - The decline in Q1 2025 gross margin was attributed to seasonal impacts, increased operational costs from hiring, and regulatory changes [4] - The company is implementing measures to stabilize gross margins, including enhancing internal controls, optimizing organizational structure, and investing in technological innovations [4][5] Group 6: Future Outlook and Strategic Initiatives - The company plans to continue exploring AI and new technologies in clinical trial execution to improve service quality and efficiency [3][4] - Proris is actively engaging in mergers and acquisitions, considering strategic alignment and valuation in its decision-making process [6][7]